A Crossover Study to Assess the Bioequivalence of the Phase III and Commercial Risedronate 35 mg Delayed Release Formulations.

Trial Profile

A Crossover Study to Assess the Bioequivalence of the Phase III and Commercial Risedronate 35 mg Delayed Release Formulations.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2011

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Male osteoporosis; Postmenopausal osteoporosis
  • Focus Pharmacokinetics
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 19 Jun 2009 Planned number of patients changed from 312 to 538 as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top